Sort   by:  
 Page size 
TranscriptomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (LNCaP)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36434 | biostudies-arrayexpress
TranscriptomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (xenografts)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36433 | biostudies-arrayexpress
GenomicsHes6 drives a critical AR transcriptional program to induce castration resistant prostate cancer through activation of an E2F1-mediated cell cycle network
Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance, other factors such as c-Myc and the E2F family also play a role in later stage disease. Here we show that Hes6 is up-regulated in aggressive human prost...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-49832 | biostudies-arrayexpress
GenomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (cMyc ChIP-seq)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-37617 | biostudies-arrayexpress
GenomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (E2F1 ChIP-seq)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36614 | biostudies-arrayexpress
TranscriptomicsGene expression in benign and prostate cancer tissue
Benign prostate tissue and prostate cancer tissue (untreated, androgen deprivation therapy responding, or castrate-resistant) was collected from patients at the time of transurethral resection of the prostate surgery. 24 samples, technical replicates.
ORGANISM(S): Homo sapiens 
2012-12-01 | E-GEOD-28680 | biostudies-arrayexpress
TranscriptomicsRNAseq profiling of tumor, tumor-draining-lymph nodes, blood and tumor-associated macrophages of MC38 mice treated with the PI3Kg inhibitor AZD3458 and a combination of AZD3458 and anti-PD-1
RNAseq profiling of AZD3458 monotherapy and combination treatment with anti-PD-1 of whole tumors, isolated tumor macrophages (Mac) (CD45+CD11b+F4/80+), whole blood (PB) and tumor draining lymph nodes (TDLN) were assessed to elucidate further mechanisms leading to enhanced combination activity.
ORGANISM(S): Mus musculus 
2021-02-28 | E-MTAB-10057 | biostudies-arrayexpress
UnknownThe metabolic phenotype of the patient influences the reduction in carotid intima-media thickness achieved following metabolic surgery.

Objectives

To determine whether metabolic phenotype is associated with the change in carotid intima-media thickness (CIMT) in patients undergoing bariatric /metabolic surgery (BMS).

Methods

We performed a case-control study of BMS candidates who had metabolically unhealthy obesity (MU...
S-EPMC9709181 | biostudies-literature
UnknownDifferentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.

Background

There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC).

Objective

To investigate clinical laboratory markers of SARS-CoV-2 and PASC.

Design

Propensity score-weighted linear regression models were fitted to evaluate d...
S-EPMC11408082 | biostudies-literature
UnknownOlfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.

Importance

Olfactory dysfunction is common after SARS-CoV-2 infection and has been associated with cognitive loss in other conditions. Formal testing is needed to characterize the presence, severity, and patterns of olfactory dysfunction.

Objective

To characterize long-term olfactory ...
S-EPMC12464792 | biostudies-literature
Sort   by:  
 Page size